BCMA Bispecific Toxicities, Access Considerations

A roundtable discussion, moderated by Saad Usmani, MD, of Memorial Sloan Kettering Cancer Center, focused on treatment considerations for relapsed or refractory multiple myeloma, including updated data from ASCO 2023. Dr. Usmani was joined by a panel that included Yi Lin, MD; Shambavi Richard, MD; and Meera Mohan, MD.

In the next segment of the roundtable series, toxicities such as cytokine release syndrome and commercial access to therapy as it relates to BCMA bispecific antibodies for myeloma are discussed.